These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38017299)

  • 41. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with
    Hwang SM; Kim BJ; Lee JS; Seong MW; Seo SH; Paik JH; Kim SA; Lee JY; Lee JO; Chang YH; Bang SM
    Ann Lab Med; 2022 Nov; 42(6):678-682. PubMed ID: 35765876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing the miRNA sponge potential of RUNX1T1 in t(8;21) acute myeloid leukemia.
    Junge A; Zandi R; Havgaard JH; Gorodkin J; Cowland JB
    Gene; 2017 Jun; 615():35-40. PubMed ID: 28322996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
    Gao HT; Zhang Y; Sun K; Guo JM; Chen YQ; Chen XL; Shi J; Niu XN; Wang F; Huo L
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):210-215. PubMed ID: 28395444
    [No Abstract]   [Full Text] [Related]  

  • 45. Hemophagocytic Lymphohistiocytosis in
    Huang X; Long F; Zhang Y; Gao X; Li T
    Turk J Haematol; 2023 Aug; 40(3):210-212. PubMed ID: 37519108
    [No Abstract]   [Full Text] [Related]  

  • 46. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.
    Duque-Afonso J; Solari L; Essig A; Berg T; Pahl HL; Lübbert M
    Br J Haematol; 2011 Jun; 153(5):612-22. PubMed ID: 21488857
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang Y; Zhou Z; Yan H; You Y
    Front Immunol; 2022; 13():810284. PubMed ID: 35185899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical Prognostic Factors Analysis of Initially Treated AML Children with t(8;21)/RUNX1-RUNX1T1
    Fan GL; Jiang PJ; Yuan M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1510-1515. PubMed ID: 33067946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
    Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new complex translocation (8;22;21)(q22;q12;q22) in RUNX1/RUNX1T1 acute myeloid leukaemia.
    Tay Za K; Shanmugam H; Chin EFM
    Malays J Pathol; 2019 Dec; 41(3):333-338. PubMed ID: 31901918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.
    Steinauer N; Guo C; Huang C; Wong M; Tu Y; Freter CE; Zhang J
    Blood Adv; 2019 May; 3(9):1379-1393. PubMed ID: 31040112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
    Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
    Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
    Thomas ME; Qi W; Walsh MP; Ma J; Westover T; Abdelhamed S; Ezzell LJ; Rolle C; Xiong E; Rosikiewicz W; Xu B; Loughran AJ; Pruett-Miller SM; Janke LJ; Klco JM
    Leukemia; 2024 May; 38(5):991-1002. PubMed ID: 38454121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Expression of CD19 and CD56 in AML Patients with RUNX1-RUNX1T1 Mutation and Its Clinical Significance].
    Hu ZL; Zhang F; Huang BJ; Pan SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):727-732. PubMed ID: 29950211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia.
    Grinev VV; Barneh F; Ilyushonak IM; Nakjang S; Smink J; van Oort A; Clough R; Seyani M; McNeill H; Reza M; Martinez-Soria N; Assi SA; Ramanouskaya TV; Bonifer C; Heidenreich O
    Nat Commun; 2021 Jan; 12(1):520. PubMed ID: 33483506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse.
    Ommen HB; Ostergaard M; Yan M; Braendstrup K; Zhang DE; Hokland P
    Eur J Haematol; 2010 Feb; 84(2):128-32. PubMed ID: 19891700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
    Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.
    Qian Y; Zhang X; Mao S; Wei W; Lin X; Ling Q; Ye W; Li F; Pan J; Zhou Y; Zhao Y; Huang X; Huang J; Tong H; Sun J; Jin J
    Mol Oncol; 2023 Jul; 17(7):1402-1418. PubMed ID: 36567628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.